Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs HUTCHMED (China) Limited

SG&A Expenses: BioMarin vs. HUTCHMED - A Decade of Growth

__timestampBioMarin Pharmaceutical Inc.HUTCHMED (China) Limited
Wednesday, January 1, 201430215600026684000
Thursday, January 1, 201540227100029829000
Friday, January 1, 201647659300039578000
Sunday, January 1, 201755433600043277000
Monday, January 1, 201860435300048645000
Tuesday, January 1, 201968092400052934000
Wednesday, January 1, 202073766900061349000
Friday, January 1, 2021759375000127125000
Saturday, January 1, 2022854009000136106000
Sunday, January 1, 2023937300000133175999
Monday, January 1, 20241009025000
Loading chart...

Cracking the code

A Comparative Analysis of SG&A Expenses: BioMarin vs. HUTCHMED

In the competitive landscape of the pharmaceutical industry, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of BioMarin Pharmaceutical Inc. and HUTCHMED (China) Limited from 2014 to 2023.

BioMarin has consistently outpaced HUTCHMED in SG&A spending, reflecting its expansive operational scale. Over the decade, BioMarin's SG&A expenses surged by approximately 210%, peaking in 2023. In contrast, HUTCHMED's expenses grew by nearly 400%, albeit from a smaller base, indicating aggressive expansion strategies.

This financial trajectory highlights BioMarin's established market presence and HUTCHMED's rapid growth ambitions. Investors and industry analysts can glean insights into each company's strategic priorities and market positioning through these financial patterns.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025